Popular on Rezul
- No Limits Method Revolutionizes Neurodivergent Education Through Embodied Cognition - 107
- Corner Property Management Welcomes Seneca Reserve HOA! - 104
- Kaplan Morrell Applauds Passage of Landmark Workers' Compensation Reform in Colorado
- First AI Marketing Platform Built Specifically for Small Businesses Launches Public Beta
- TEDxInglewood Returns to The Miracle Theater on August 9, 2025 — Celebrating Bold Ideas and Community Energy
- Rediscovered Christopher Lee Recording 'Elenore' Re-Released to Mark 10th Anniversary of His Passing
- Conexwest Expands Single-Phase Cold Storage Lineup: Versatile Solutions for Diverse Temperature Needs
- Honoring Black History, Culture, and Community in Fall River
- Manhattan Boutique Real Estate Collaborates with InterContinental Hotels NYC in a Branding Partners Personalized Approach
- Token-Operated Sake Service Opens at Tobu Nikko Station
Similar on Rezul
- Digital Watchdog Launches New myDW Cloud Services
- Infinite Health Introduces Cutting-Edge Regenerative Medicine for Wound Care with Trip Goolsby, MD
- Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
- Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
- Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
- $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
- New AI Academy Helps Therapists Embrace Tech Without Losing Their Humanity
- Coker Completes Acquisition of Healthcare Cost Solutions, a Leading Expert in Technology-Enabled Compliance Services
NLX-112 Restores Motor Function in a Transgenic Model of Spinocerebellar Ataxia
Rezul News/10508844
CASTRES, France - Rezul -- A research team specialized in the study of nervous system disorders has found that NLX-112, a serotonin 5-HT1A receptor agonist developed by Neurolixis, reversed motor deficits in a transgenic model of Spinocerebellar ataxia3 (SCA3), a rare genetic orphan disease. The team led by Prof. Patricia Maciel, at the University of Minho, Portugal, reported online in the journal, Neurobiology of Disease, that NLX-112 restored motor function in nematode worms that express the same gene mutation as that seen in SCA3 patients.
Prof. Maciel commented: "SCA3, also known as Machado-Joseph disease, is an inherited condition. Symptoms including clumsiness, loss of strength, and tremor in the arms and legs that worsen over time, eventually leading to very severe disability. Our new data suggest that NLX-112 may improve the condition of patients suffering from this debilitating disorder."
Neurolixis is now collaborating with Prof. Maciel's team to test NLX-112 in transgenic SCA3 mice. The project, supported by the US Dept. of Defense, will determine whether extended NLX-112 administration attenuates SCA3 symptoms and slows down their development.
More on Rezul News
Adrian Newman-Tancredi, CEO of Neurolixis commented: "SCA3 is incurable and there is no approved treatment. If the results seen in the transgenic nematode worm model are translated to transgenic SCA3 mice, Neurolixis will seek to develop NLX-112 in clinical trials for SCA3 patients. NLX-112 has previously been tested in over 500 patients for other indications so we know it is safe and well tolerated."
NLX-112 is currently undergoing a clinical Phase 2A study for treatment of L-DOPA-induced dyskinesia in Parkinson's disease patients and the new SCA3 data suggests that it may also have utility for treatment of additional movement disorders.
Full publication – Open Access
Identification of the 5-HT1A serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease.
Pereira-Sousa et al., Neurobiology of Disease, 28 Jan 2021 (Online ahead of print)
doi: 10.1016/j.nbd.2021.105278, PMID: 33516872
About Neurolixis
Neurolixis is a privately held biotechnology company developing therapies for central nervous system disorders. It has two lead compounds, NLX‑112 (Phase 2) which targets treatment of motor disorders, and NLX-101 (Phase 1), a potential rapid-acting anti-depressant, with utility for treating neuro-developmental disorders including Rett syndrome. In addition, Neurolixis conducts a drug discovery program targeting chronic pain (non-opioid mechanism) and depression.
More on Rezul News
About the University of Minho
The mission of University of Minho, founded in 1973, is to create, spread and convert knowledge into value-generating applications. The Life and Health Sciences Research Institute (ICVS) is the Biomedicine R&D Unit of the School of Medicine cluster of the University. The cluster includes 2CA-Braga, a clinical research site that currently runs 1/3 of all clinical trials in Portugal; P5, that with the ICVS conceives and develops new digital medicine products and provides medical services with a digital interface; and B.ACIS, a knowledge transfer interface fostering developments in biomedical research resulting in marketed products that bring clinical benefits to patients.
Prof. Maciel commented: "SCA3, also known as Machado-Joseph disease, is an inherited condition. Symptoms including clumsiness, loss of strength, and tremor in the arms and legs that worsen over time, eventually leading to very severe disability. Our new data suggest that NLX-112 may improve the condition of patients suffering from this debilitating disorder."
Neurolixis is now collaborating with Prof. Maciel's team to test NLX-112 in transgenic SCA3 mice. The project, supported by the US Dept. of Defense, will determine whether extended NLX-112 administration attenuates SCA3 symptoms and slows down their development.
More on Rezul News
- Lore Link is Here to Help Organize Your Game
- Chappaqua's Annual Townwide Summer Sale – Unbeatable Savings at Your Favorite Local Boutiques!
- Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors
- Garden City Realty recognizes top REALTOR®s of the Month and Quarter
- Maui Investment Property Realtor Shares the Wonders of Stargazing on Maui!
Adrian Newman-Tancredi, CEO of Neurolixis commented: "SCA3 is incurable and there is no approved treatment. If the results seen in the transgenic nematode worm model are translated to transgenic SCA3 mice, Neurolixis will seek to develop NLX-112 in clinical trials for SCA3 patients. NLX-112 has previously been tested in over 500 patients for other indications so we know it is safe and well tolerated."
NLX-112 is currently undergoing a clinical Phase 2A study for treatment of L-DOPA-induced dyskinesia in Parkinson's disease patients and the new SCA3 data suggests that it may also have utility for treatment of additional movement disorders.
Full publication – Open Access
Identification of the 5-HT1A serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease.
Pereira-Sousa et al., Neurobiology of Disease, 28 Jan 2021 (Online ahead of print)
doi: 10.1016/j.nbd.2021.105278, PMID: 33516872
About Neurolixis
Neurolixis is a privately held biotechnology company developing therapies for central nervous system disorders. It has two lead compounds, NLX‑112 (Phase 2) which targets treatment of motor disorders, and NLX-101 (Phase 1), a potential rapid-acting anti-depressant, with utility for treating neuro-developmental disorders including Rett syndrome. In addition, Neurolixis conducts a drug discovery program targeting chronic pain (non-opioid mechanism) and depression.
More on Rezul News
- Houston Office Market Report | Q2 2025
- Yes, Islamorada is The Fishing Capital of The World, Here's Why!
- Corner Property Management Selected as New Management Company for Orange COA
- AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
- Construcción del Corredor Norte–Sur (NSC) de Singapur
About the University of Minho
The mission of University of Minho, founded in 1973, is to create, spread and convert knowledge into value-generating applications. The Life and Health Sciences Research Institute (ICVS) is the Biomedicine R&D Unit of the School of Medicine cluster of the University. The cluster includes 2CA-Braga, a clinical research site that currently runs 1/3 of all clinical trials in Portugal; P5, that with the ICVS conceives and develops new digital medicine products and provides medical services with a digital interface; and B.ACIS, a knowledge transfer interface fostering developments in biomedical research resulting in marketed products that bring clinical benefits to patients.
Source: NEUROLIXIS
0 Comments
Latest on Rezul News
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- Salazar Heating, Cooling & Plumbing Launches Water Conservation Initiative to Help Santa Fe Homeowners Cut Water Waste
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
- Winners Development Corporation Pioneers Skyscraper In South Dallas
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
- Extreme Exterior Cleaning of Seaside Florida Home Separates Pros from Amateurs
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
- The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
- San Antonio Board of REALTORS® Among First to Use Passkey Login with Solid Earth's SSO Dashboard
- CGI+ Sells Multifamily Development Site in Los Angeles' South Bay to JPI for $40 Million
- $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
- Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
- Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
- Franco Polished Plaster Celebrates 35 Years of Bringing Walls to Life in the UK
- Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
- Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
- Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles
- All Saints Carpet Cleaning -- Why Fast Dry Shampooing Is The Best!